Research indicated that neuronal injury-related biomarkers of YKL-40 and NfL are valuable tools for staging and predicting patients within the ALS/FTD clinical spectrum [70], as a disease progression biomarker in genetic frontotemporal dementia [45,71], or in distinguishing behavioral variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PSY) [72]. The gene discussed is CHI3L1; the disease is frontotemporal dementia.